Patel Anish 4

What Happened

• Anish Patel, listed as Enliven Therapeutics' COO, received awards on February 12, 2026: 20,000 shares acquired at $0.00 and 120,000 derivative shares reported at $0.00 (restricted stock units). The reported dollar value of the grants is $0 because these are equity awards, not a cash purchase.
• The 120,000 derivative units are restricted stock units (RSUs) that convert to common shares upon vesting; the 20,000 shares appear as immediate holdings (held by a family trust for which Patel is trustee).

Key Details

• Transaction date: February 12, 2026; Form 4 filed February 17, 2026.
• Prices: both entries reported at $0.00 (awards/grants, not purchases).
• Award totals: 20,000 shares + 120,000 RSUs granted.
• Vesting (RSUs): per footnote, 1/4 of the RSUs vest on March 1, 2027, then 1/16th vest each June 1, Sept 1, Dec 1 and March 1 thereafter, subject to continued service.
• Family trust: the 20,000 shares are held by The Patel / Dong Family Trust (Patel is trustee).
• Separate vesting note (footnote F3) describes an option schedule (1/4 vesting after one year, then monthly thereafter); no option exercise is reported in this Form 4.
• Filing timing: the Form 4 was filed five days after the reported transactions (Feb 12 → Feb 17), which appears to exceed the typical 2-business-day reporting window for insiders.
• Officer status: the filing notes Patel is no longer deemed an executive officer under Section 16 after February 12, 2026.

Context

• These entries are grants/awards (not open-market purchases or sales). Awards and RSUs are common compensation tools and do not by themselves indicate buying or selling sentiment.
• The RSUs are contingent on continued service and vest gradually, so shares will be issued over time if vesting conditions are met.
• Because the Form 4 includes both immediate shares (held in a family trust) and RSUs, retail investors should view this as compensation-related equity rather than a direct personal market investment.